• Je něco špatně v tomto záznamu ?

Analysis of prognostic significance of merkel cell polyomavirus in chronic lymphocytic leukemia

J. Trizuljak, J. Srovnal, K. Plevová, Y. Brychtová, L. Semerád, D. Bakešová, E. Létalová, A. Benedíková, J. Mayer, M. Hajdúch, Š. Pospíšilová, M. Doubek,

. 2015 ; 15 (7) : 439-442. [pub] 20150211

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010472

Grantová podpora
NT13493 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Merkel cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukemia (CLL). Previous studies have reported conflicting results on the frequency and potential pathogenetic role of MCPyV in CLL. The aim of this study was to evaluate MCPyV's association with CLL and its prognostic significance. PATIENTS AND METHODS: Between 2006 and 2013, DNA samples obtained from CLL patients (n = 119) before treatment were tested for MCPyV using quantitative real-time polymerase chain reaction analysis and verified by gel electrophoresis. Only samples testing positive by both methods were considered valid. RESULTS: We found that 13 (11%) of 119 CLL cases were positive for MCPyV. Between the groups of MCPyV-positive and -negative patients, there was no significant difference in the sex, age, cytogenetics, presence of p53 defect, or immunoglobulin heavy chain (IGHV) mutational status. In the subset of MCPyV-negative patients, advanced Rai stage (III to IV) was found more frequently, and therapy was initiated more often. There was no difference in overall response rate, median progression-free survival, and overall survival between both groups. We did not observe any new positivity after treatment in initially MCPyV-negative patients. CONCLUSION: This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010472
003      
CZ-PrNML
005      
20240717105559.0
007      
ta
008      
160408s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2015.02.003 $2 doi
024    7_
$a 10.1016/j.clml.2015.02.003 $2 doi
035    __
$a (PubMed)25758600
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Trizuljak, Jakub $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic. $7 xx0230707
245    10
$a Analysis of prognostic significance of merkel cell polyomavirus in chronic lymphocytic leukemia / $c J. Trizuljak, J. Srovnal, K. Plevová, Y. Brychtová, L. Semerád, D. Bakešová, E. Létalová, A. Benedíková, J. Mayer, M. Hajdúch, Š. Pospíšilová, M. Doubek,
520    9_
$a BACKGROUND: Merkel cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukemia (CLL). Previous studies have reported conflicting results on the frequency and potential pathogenetic role of MCPyV in CLL. The aim of this study was to evaluate MCPyV's association with CLL and its prognostic significance. PATIENTS AND METHODS: Between 2006 and 2013, DNA samples obtained from CLL patients (n = 119) before treatment were tested for MCPyV using quantitative real-time polymerase chain reaction analysis and verified by gel electrophoresis. Only samples testing positive by both methods were considered valid. RESULTS: We found that 13 (11%) of 119 CLL cases were positive for MCPyV. Between the groups of MCPyV-positive and -negative patients, there was no significant difference in the sex, age, cytogenetics, presence of p53 defect, or immunoglobulin heavy chain (IGHV) mutational status. In the subset of MCPyV-negative patients, advanced Rai stage (III to IV) was found more frequently, and therapy was initiated more often. There was no difference in overall response rate, median progression-free survival, and overall survival between both groups. We did not observe any new positivity after treatment in initially MCPyV-negative patients. CONCLUSION: This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients.
650    _2
$a elektroforéza v polyakrylamidovém gelu $7 D004591
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a těžké řetězce imunoglobulinů $x genetika $7 D007143
650    _2
$a chronická lymfatická leukemie $x diagnóza $x virologie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a Merkelův polyomavirus $x patogenita $7 D059965
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a polyomavirové infekce $x diagnóza $x virologie $7 D027601
650    _2
$a prevalence $7 D015995
650    _2
$a prognóza $7 D011379
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a infekce onkogenními viry $x diagnóza $x virologie $7 D014412
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Srovnal, Josef $u Institute of Molecular and Translational Medicine, Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University, and Faculty Hospital Olomouc, Czech Republic. $7 xx0091239
700    1_
$a Plevová, Karla $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. $7 xx0158852
700    1_
$a Brychtová, Yvona $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic. $7 xx0105542
700    1_
$a Semerád, Lukáš $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic. $7 xx0233574
700    1_
$a Bakešová, Denisa $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic. $7 xx0320064
700    1_
$a Létalová, Eva $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic.
700    1_
$a Benedíková, Andrea $u Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. $7 xx0169440
700    1_
$a Mayer, Jiří, $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. $d 1960- $7 nlk20000083651
700    1_
$a Hajdúch, Marián, $u Institute of Molecular and Translational Medicine, Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University, and Faculty Hospital Olomouc, Czech Republic. $d 1969- $7 xx0050218
700    1_
$a Pospíšilová, Šárka, $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. $d 1969- $7 xx0101843
700    1_
$a Doubek, Michael, $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. Electronic address: mdoubek@fnbrno.cz. $d 1972- $7 mzk2004217554
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 15, č. 7 (2015), s. 439-442
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25758600 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20240717105554 $b ABA008
999    __
$a ok $b bmc $g 1113901 $s 934840
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 15 $c 7 $d 439-442 $e 20150211 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
GRA    __
$a NT13493 $p MZ0
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...